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Summary
OBJECTIVES: In Switzerland, universal health insurance
does not cover any routine testing for sexually transmitted
infections (STIs), not even in individuals at high risk, and
extra-genital swabbing is not standard of care. We com-
pared STI prevalence in a multicentre prospective obser-
vational cohort of multi-partner women with/without sex
work and evaluated associated risk factors.
MATERIALS AND METHODS: Between January 2016
and June 2017, we offered free STI testing to women with
multiple sexual partners (three or more in the previous
12 months), with follow-up examinations every 6 months.
We used multiplex polymerase chain-reaction testing (for
Neisseria gonorrhoeae, Chlamydia trachomatis, Tri-
chomonas vaginalis, Mycoplasma genitalium) for pooled
swabs (pharynx, urethra/vagina, anus), and antibody tests
for human immunodeficiency virus (HIV) and Treponema
pallidum at every visit, and for hepatitis B and C at base-
line.
RESULTS: We screened 490 female sex workers (FSWs),
including 17 trans women, and 92 other multi-partner
women. More than half reported a steady partner. Previ-
ously undiagnosed HIV was found in 0.2% vs 0.0%, re-
spectively, and T. pallidum antibodies in 5.9% vs 0.0%.
STIs requiring antibiotic treatment comprised: active
syphilis 1.2% vs 0.0%; N. gonorrhoeae 4.9% vs 0.0%; C.
trachomatis 6.3% vs 5.4%, T. vaginalis 10.4% vs 0.0%;
M. genitalium 6.7% vs 6.5%. One in four FSWs vs one in
nine other women had one or more of these STIs at base-
line. 15.8% vs 3.8% had a history of hepatitis B, 45.5%
vs 22.8% had no immunity (HBs-AB <10 IU/l). Two FSWs
had hepatitis C virus antibodies (0.4%) without concur-
rent HIV infection. Non-condom-use (last three months)
for anal/vaginal sex was not associated with STIs. Inde-
pendent risk factors were group sex (adjusted odds ratio
[aOR] 2.1, 95% confidence interval [CI] 1.1–4.0), age less
than 25 (aOR 3.7, 95% CI 1.6–8.9), and being active in
sex work for less than 1 year (aOR 2.7, 95% CI 1.3–5.3).
CONCLUSION: HIV and HCV do not appear to pose a
major public health problem among FSWs in Switzerland,
whereas vaccination against HBV should be promoted.
FSWs showed high rates of STIs requiring treatment to re-
duce transmission to clients and/or steady partners. FSWs
should be offered low-cost or free STI screening as a pub-
lic health priority.
Keywords: sexually transmitted diseases, hepatitis B,
HIV, sexual behaviour, sex work
Editorial note
We decided to publish the main results of the Swiss STAR
trial as two separate publications – one on the sub-sample
of men, another on the sub-sample of women. Reasons for
this include anatomical and epidemiological differences,
and the medical disciplines in charge: urology and infec-
tious diseases for men, and gynaecology for women. Fur-
thermore, the two main target groups, men who have sex
with men and female sex workers, differ with respect to
the legal and societal context of sexual contacts, all of
this probably resulting in distinct readerships. The detailed
joint methods for both publications are available as online
supplement.
Four key messages
1. In Switzerland five FSWs need to be screened for non-
viral STIs to find one with clinically relevant infec-
tion: syphilis, gonorrhoea, chlamydia, trichomoniasis
(excluding M. genitalium).
Correspondence:
Dr med. Axel Jeremias
Schmidt, MPH, Cantonal
Hospital St. Gallen, Divi-
sion of Infectious Diseases
and Infection Control,
Rorschacherstrasse 95,
CH-9007 St. Gallen, axelje-
remias.schmidt[at]kssg.ch
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 1 of 10
2. In the interest of public health, regular screening for
syphilis, gonorrhoea and chlamydia should be offered
to FSWs in Switzerland free of charge.
3. Hepatitis B vaccination is lacking in many FSWs in
Switzerland and the promotion of free vaccination
should be considered.
4. HIV and HCV infections do not appear to be a public
health priority for female sex workers in Switzerland
Introduction
In addition to behavioural changes and vaccination, early
detection and effective treatment of sexually transmissible
infections (STIs) are important for the prevention of STIs
[1]. Any STI can occur to a variable extent in an asymp-
tomatic stage. Mucosal shedding and transmission of in-
fectious pathogens is known for all STIs in the absence of
symptoms. However, the risk of transmission might vary
for different pathogens and anatomical sites. The role of
asymptomatic carriers depends on the number of partners
and the type of sexual network [2]. Importantly, asympto-
matic genital shedding of an STI in a sex worker might
have an impact on the epidemiology of that STI, given the
high number of partners of the asymptomatically infected
individual.
Accordingly, the Swiss National Programme on human im-
munodeficiency virus (HIV) and other STIs 2011–2017
highlights the importance of early detection and correct
treatment of STIs in the context of sex work [1]. However,
due to the current design of the Swiss health insurance
system, the cost for routine testing for STIs in otherwise
healthy individuals has to be paid almost exclusively by
the individual. This cost is a disincentive for an asympto-
matic individual to undergo STI testing.
If Swiss published recommendations for STI testing are
closely followed and swabs from different anatomical sites
are therefore not pooled [3], testing costs for syphilis, gon-
orrhoea, and chlamydia easily add up to an equivalent of
more than US$ 700 or, when adjusted for purchasing pow-
er parity, of almost US$ 600 PPP [4]. The STAR trial
(STI-Testing of Asymptomatic individuals at Risk) was
initiated to examine the likely cost of a new financing sys-
tem for such procedures. The aim was to define ideal tar-
get groups for free STI screening based on behavioural risk
factors.
The prevalence and incidence of STIs in female sex work-
ers (FSWs) in Switzerland is largely unknown. The prima-
ry objective of the STAR trial was to describe the preva-
lence of HIV and common non-viral STIs across different
behavioural/demographic risk categories, with a focus on
two populations known to have an increased risk for STIs:
men who have sex with men (MSM) [5] and FSWs. Sec-
ondary objectives were to describe the incidence of infec-
tions with HIV and common non-viral STIs in these two
groups, the prevalence of uncleared hepatitis B, and to
compare self-reported with actual hepatitis B vaccination
status / immunity.
This paper presents the results for the population of cisgen-
der (assigned female at birth) and transgender (assigned
male at birth) FSWs and a small comparison group of mul-
ti-partner women who had not been paid for sex.
Materials and methods
Across Switzerland, between January 2016 and June 2017,
we offered free STI-testing to men and women with mul-
tiple (three or more in the last 12 months) sexual partners
attending multiple STI testing sites. The study provided
follow-up examinations every six months. We used mul-
tiplex polymerase chain-reaction testing (PCR) (for Neis-
seria gonorrhoeae, Chlamydia trachomatis, Trichomonas
vaginalis, Mycoplasma genitalium) of pooled swabs (phar-
ynx, urethra/vagina, anus), and antibody tests for HIV and
Treponema pallidum (IgG/M, plus rapid plasma reagin if
positive) at every visit, and for hepatitis B and C at base-
line. At every visit, participants self-completed an anony-
mous online questionnaire. The detailed methods are de-
scribed in appendix 1.
Ethical approval was given on 21 July 2015 by the lead
ethics committee Eastern Switzerland (EKOS) under
BASEC PB_2016-00738, and subsequently approved by
ethics committees in Bern (KEK BE), Basel (EKNZ), Vaud
(CER-VD), and Zurich (KEK ZH).
Results
We enrolled 490 female sex workers (FSWs, including 17
trans women) and 92 other multi-partner women who were
not paid for sex. Overall, 49 women returned at least once
for follow-up, resulting in a rate of 8% and 29.5 person-
years of follow-up. All participants received all HIV/STI
tests; for two FSWs hepatitis C virus (HCV)-RNA could
not be determined because one centre used the wrong sam-
pling tubes; they were excluded from the respective analy-
ses.
Sociodemographic characteristics at baseline
Participants resided almost entirely in the German-speak-
ing part of Switzerland. Enrolment of FSW participants
started slowly and peaked more than a year after study ini-
tiation, in March 2017. Most FSWs were recruited in ded-
icated FSW health centres or through outreach work or-
ganised by those centres; most other women were recruited
in participating clinics. Among FSWs, 3.5% were trans-
gender women and 0.2% had HIV diagnosed prior to en-
rolment (i.e., one cisgender FSW from a high-prevalence
country). Median age was 31 years among FSWs vs 30
among other multi-partner women. Less than 3% of FSWs
were Swiss, almost half of them were nationals of eastern
or south-eastern Europe (predominantly Bulgaria and Ro-
mania), one third were nationals of Latin America, Portu-
gal or Spain; among other multi-partner women Swiss na-
tionality was over-represented compared with the general
population. Of the FSWs, 13% had no permit and 70% had
entered the country with a short-term permit or as a tourist.
Overall, 78% said that their entire income was based on
sex work and only 22% had health insurance in Switzer-
land. The median time spent in sex work was 3 years, with
an interquartile range (IQR) of 1–7. Table 1 shows the so-
ciodemographics of participants.
Risk and precautionary behaviour
Overall (excluding women with missing answers), 49% of
FSWs vs 90% of other multi-partner women reported full
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Persons with baseline visit N = 490 N = 92
Persons with follow-up visits N = 42 N = 7
Follow-up visits N = 46 N = 7
Follow-up rate 42/490 (8.6) 7/92 (7.6)
Person years of follow-up 25.4 years 4.1 years
Location of VCT centre in Switzerland French-speaking part 13/490 (2.7) 4/92 (4.3)
German-speaking part 477/490 (97.3) 88/92 (95.7)
Service recruited at Dedicated FSW health centre 340/490 (69.4) 0/92 (0.0)
General hospital 117/490 (23.9) 88/92 (95.7)
Other VCT centre 33/490 (6.7) 4/92 (4.3)
Sociodemographic parameters
Especially vulnerable groups Transgender (MtF) 17/490 (3.5) 5/92 (5.4)
Previously diagnosed HIV 1/490 (0.2) 0/92 (0.0)
Age <25 years 95/490 (19.4) 14/92 (15.2)
25–39 years 276/490 (56.3) 70/92 (76.1)
40+ years 119/490 (24.3) 8/92 (8.7)
Median (IQR) 31 (26; 39) 30 (26; 34)
Nationality Swiss 13/490 (2.7) 81/92 (88.0)
Neighbouring countries: AT, DE, FR, IT 29/490 (5.9) 7/92 (7.6)
Latin American, ES, PT 158/490 (32.2) 0/92 (0.0)
Other Western European, US, CA 1/490 (0.2) 0/92 (0.0)
Eastern and south-eastern European 237/490 (48.4) 3/92 (3.3)
African 35/490 (7.1) 1/92 (1.1)
Asian 11/490 (2.2) 0/92 (0.0)
Unknown 6/490 (1.2) 0/92 (0.0)
Legal status Swiss 13/490 (2.7) 81/92 (88.0)
Settlement permit 24/490 (4.9) 9/92 (9.8)
Renewable/commuter permit 47/490 (9.6) 1/92 (1.1)
Short-term permit or tourist 342/490 (69.8) 1/92 (1.1)
No permit 64/490 (13.1) 0/92 (0.0)
Income through sex work None / not applicable 0/444 (0.0) 92/92 (100.0)
Less than half 64/444 (14.4) n.a.
More than half 34/444 (7.7) n.a.
Entire income 346/444 (77.9) n.a.
Active in sex work for less than 1 year 88/490 (18.1) n.a.
Health insurance in Switzerland 110/485 (22.4) 88/90 (95.7)
Single / No steady partnership 161/336 (47.9) 43/91 (47.3)
Non-heterosexual identity* 19/490 (3.9) 18/92 (19.6)
Risk and precautionary behaviours
Reports hepatitis B vaccination† 64/130 (49.2) 61/68 (89.7)
Reports HPV vaccination† 9/239 (3.8) 13/77 (16.9)
Previous history of diagnosed STIs‡ 105/490 (21.4) 20/92 (21.7)
Number of sexual partners, last 12 months 3–5 15/490 (3.1) 66/92 (71.7)
6–10 19/490 (3.9) 17/92 (18.5)
11–20 27/490 (5.5) 5/92 (5.4)
21–50 64/490 (13.1) 2/92 (2.2)
50+ 365/490 (74.5) 2/92 (2.2)
Bought sex since last HIV test 13/490 (2.7) 3/92 (3.3)
Sex in a group, previous 12 months No 303/490 (61.8) 84/92 (91.3)
Yes, longer than 6 weeks ago 41/490 (8.4) 8/92 (8.7)
Yes, in the last 6 weeks 146/490 (29.8) 0/92 (0.0)
Online acquisition of sex partners None, previous 12 months 444/490 (90.6) 63/92 (68.5)
Less than half, previous 12 months 19/490 (3.9) 17/92 (18.5)
Half or more, previous 12 months 27/490 (5.5) 12/92 (13.0)
CAVI, previous 3 months 267/490 (54.5) 47/92 (51.1)
IDU, previous 12 months 2/481 (0.4) 0/90 (0.0)
Sexualised drug use§ 49/490 (14.4) 21/91 (23.3)
AT = Austria; CA = Canada; CAVI = condomless anal or vaginal intercourse; DE = Germany; ES = Spain; FR = France; FSW = female sex worker; HPV = human papilloma virus;
IDU = injection drug use; IQR = interquartile range; IT = Italy; MtF = male to female transition; PT = Portugal; STI = sexually transmitted infection US = United States of America;
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VCT = voluntary counselling and testing * Identifying as homosexual, bisexual, or other (but not as heterosexual). † Excluding participants who said they don’t know. ‡ It was not
specified what counted as an STI (other than HIV). § Sexualised drug use, consumption of poppers, cannabis, cocaine or synthetic drugs before or during sex.
vaccination against hepatitis B virus (HBV). Human papil-
loma virus (HPV vaccination was reported by 4% vs 17%.
A very similar proportion reported a history of previously
diagnosed STIs, 21% of FSWs and 22% of other women.
In contrast, the median number of sexual partners was 50+
among FSWs, but was a magnitude lower (3–5) in oth-
er women, and group sex was reported by 38% vs 8.7%.
Among FSWs, 9% had met partners online in the previ-
ous 12 months, whereas online acquisition of partners was
common among other women (32%).
Sexualised drug use was reported by 14% of FSWs vs 23%
of other women. Injection drug use in the last 12 months
was rare (0.4% of FSWs). About half of the participants
(55% vs 51%) reported condomless anal or vaginal inter-
course in the past three months. Table 1 shows the risk and
precautionary behaviours of participants.
Clinical outcomes: mental health, HIV, STIs, hepatitis
B and C
In both groups one third of women showed signs of major
depression in the PHQ-2 screening tool; 17% of FSWs vs
8% of other multi-partner women were sexually unhappy
(p <0.001), and in addition, 18% of FSWs reported hav-
ing no sex life outside transactional sex. Previously undi-
agnosed HIV was found in 0.2% vs 0.0% (i.e., one trans-
gender FSW from south-eastern Europe); TP-antibodies in
5.9% vs 0.0% (p = 0.006). For STIs requiring antibiot-
ic treatment according to some guidelines at the time, we
found active syphilis in 1.4% vs 0.0%; N. gonorrhoeae
4.9% vs 0.0% (p = 0.015); C. trachomatis 6.3% vs 5.4%;
T. vaginalis 10% vs 0.0% (p <0.001); M. genitalium 6.7%
vs 6.5%. The joint measure for any of those five STIs
was 23% vs 11% (p = 0.004), corresponding to a number
needed to screen of 4 or 9, respectively. When only infec-
tions with N. gonorrhoeae, C. trachomatis, and T. pallidum
were considered to require treatment, the number needed
to screen increased to 9 among FSWs vs 19 among other
women (p = 0.068).
Concerning viral hepatitis, 16% of FSWs vs 3.8% of other
multi-partner women had a previous hepatitis B infection
(antibodies to hepatitis B core antigen [HBc-AB] positive,
p = 0.002), 1.4% vs 0.0% had chronic hepatitis B (HBc-AB
positive, antibodies to hepatitis B surface antigen [HBs-
AB] negative); and 46% vs 23% had no immunity (HBs-
AB <10 IU/l, p <0.001). Among FSWs, using this HBs-
AB cut-off, the question relating to hepatitis B vaccination
was 57% sensitive and 61% specific. Two FSWs (cisgen-
der FSWs from Latvia and Hungary) had HCV antibodies
(0.4%), one with HCV-RNA (0.2%).
Despite a rather small comparison group, the differences
were statistically significant for a history of syphilis, cur-
rent gonorrhoea, current T. vaginalis infection and for two
combined outcomes, but not for C. trachomatis and M.
genitalium. The differences were also statistically signifi-
cant for a history of hepatitis B and lack of corresponding
immunity.
Table 2 shows the clinical outcomes among all study par-
ticipants. Among FSWs, with over 25 person-years of fol-
low-up, the proportion with incident non-viral STIs over 1
year of follow-up was slightly higher than prevalent non-
viral STIs at baseline (fig. 1). No incident HIV infection
was found.
Multivariable models
In multivariable regression analysis, controlling for gender
identity and the numbers of sexual partners, inconsistent
condom-use (last 3 months) for anal/vaginal sex was not
associated with STIs. Independent risk factors were group
sex (adjusted odds ratio [aOR] 2.1, 95% confidence in-
terval [CI] 1.1–4.0), age less than 25 (aOR 3.7, 95% CI
1.6–8.9) and being active in sex work less than 1 year (aOR
2.7, 95% CI 1.3–5.3).
When also controlled for reporting symptoms, our findings
were almost identical, and the variance explained by our
model was only marginally increased. Using the alternative
outcome by adding M. genitalium and T. vaginalis did not
substantially change these findings; however all effect size
measures decreased, as did the explained variance (table
3).
Discussion
Our primary objective was to determine the prevalence of
non-viral STIs (active syphilis, gonorrhoea, C. trachoma-
tis, T. vaginalis and M. genitalium) among female sex
workers in Switzerland. We found a combined prevalence
of all five STIs of 23%, which was higher than the antici-
pated prevalence used in the sample size calculation. Non-
viral STIs were common in FSWs, but not among other
multi-partner women. Five FSWs needed to be screened
for non-viral STIs to find one with a clinically relevant
infection: syphilis, gonorrhoea, chlamydia or T. vaginalis.
Even restricting our analysis to only the three pathogens
with major clinical sequelae (active syphilis, gonorrhoea,
C. trachomatis) a prevalence of 11% indicates that these
pathogens merit further attention in this population.
The STAR trial also tried to estimate the incidence of STIs
among FSWs, but this was hampered by the low follow-
up rate (46 visits contributing to a total of 25 observation-
years). Therefore, the incidence estimates need to be inter-
preted cautiously.
Syphilis
Among the 6% of FSWs with evidence of prior syphilis in-
fection (T. pallidum IgG/M positive), one in five had ac-
tive syphilis, compared with one in ten among MSM in
the “men” part of the STAR trial [5]. This rate of active
syphilis indicates inadequate diagnosis and therapy and
highlights the importance of testing FSWs for syphilis
(with subsequent treatment of individuals with no prior
treatment) on a regular basis. The prevalence of active
syphilis in this study (1.2%) was very similar to the 1.1%
prevalence in a German study [6].
Syphilis remains asymptomatic for most of the post-prima-
ry phases, with the exception of secondary syphilis where
fever and rash are common, but underreported. The risk
of transmission of syphilis, however, remains, particularly
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within the first 2 years of infection [7]. The rate of trans-
mission of primary or secondary syphilis from an infected
individual has been estimated at 30% [8]; however, the
study included repeated sexual exposures with the source.
More recent studies investigating the per contact risk of
transmission reported a transmission risk in the range of
1–2% [9]. Gray et al. estimated the per contact risk of
transmission during the early stage of latent syphilis to be
about half the risk compared with the primary or secondary
stage [10].
Based on a Swiss survey on FSWs, Biberstein and Kilias
estimated the number of sexual acts with clients to be
approximately 2–6 million per year [11]. Assuming that
1% of FSWs are infected and a 1% risk of transmission
per event, this would result in approximately 200 to 600
syphilis transmission events from FSWs to clients, per
year. This figure is close to the reported yearly numbers of
200 syphilis cases among non-MSM men in Switzerland
[12], especially if underreporting of syphilis cases among
clients and the possibility of repeated exposures to the
same FSW are considered. Since syphilis has potentially
severe long-term consequences, prevention efforts to re-
duce the risk of transmission from FSWs to their clients are
needed.
The high estimate of the incidence for active syphilis
(3.6%) must be interpreted with caution owing to the low
follow-up rate. However, even the lower margin of the
95% confidence interval indicates a relevant risk of inci-
dent infections above the national yearly average of 2.4/
100,000 among women [12].






Persons with baseline visit N = 490 N = 92
Mental health Sexually unhappy / No private sex life* 35.8 (31.4–40.4) 7.8 (3.5–15.9)
Signs of major depression (PHQ-2 variant) 29.3 (25.2–33.7) 36.7 (28.9–33.8)
HIV Newly diagnosed HIV 0.2 (0.0–1.3) 0.0 (0.0–3.3)
All prevalent HIV 0.4 (0.1–1.6) 0.0 (0.0–3.3)
STIs Active syphilis (treatment) 1.2 (0.5–2.8) 0.0 (0.0–3.3)
T. pallidum IgG/M positive 5.9 (4.1–8.5) 0.0 (0.0–3.3)
High RPR/VDRL (reactive at 1: ≥8) 0.2 (0.0–1.3) 0.0 (0.0–3.3)
N. gonorrhoeae 4.9 (3.2–7.3) 0.0 (0.0–3.3)
C. trachomatis 6.3 (4.4–9.0) 5.4 (2.0–12.8)
T. vaginalis 10.4 (7.9–13.5) 0.0 (0.0–3.3)
M. genitalium 6.7 (4.7–9.4) 6.5 (2.7–14.2)
Active syphilis, NG, or CT 11.0 (8.5–14.2) 5.4 (2.0–12.8)
Active syphilis, NG, CT, or TV 19.0 (15.7–22.8) 5.4 (2.0–12.8)
Active syphilis, NG, CT, TV, or MG 23.1 (19.5–27.1) 10.9 (5.6–19.5)
Reporting STI symptoms† 21.0 (17.5–24.9) 21.7 (14.1–31.8)
Hepatitis B and C No. persons with HBs-AB (HBc-AB, HCV-AB) N = 490 (431, 488) N = 92 (78, n.a.)
HBs-AB <10 IU/l 45.5 (41.1–50.0) 22.8 (15.0–33.0)
HBc-AB positive 15.8 (12.6–19.7) 3.8 (2.8–7.7)
HBc-AB positive, HBs-AB negative 1.4 (0.8–1.8) 0.0 (0.0–3.8)
HCV-AB positive 0.4 (0.1–1.6) n.a.
HCV-RNA 0.2 (0.0–1.3) n.a.
HCV-AB among HIV-negative 0.4 (0.1–1.6) n.a.
HCV-RNA among HIV-negative 0.2 (0.0–1.3) n.a.
Yearly incidence during follow-up FSWs
% (95% CI)
Persons with follow-up visits n = 42
Follow-up visits n = 46
Person-years of follow-up 25.4 years
HIV Newly diagnosed HIV 0.0 (0.0–11.8)
STIs Active syphilis (treatment) 3.9 (0.6–26.9)
High RPR/VDRL (reactive at 1: ≥8) 0.0 (0.0–11.8)
N. gonorrhoeae 11.8 (4.1–34.2)
C. trachomatis 7.9 (2.1–29.8)
T. vaginalis 19.7 (9.0–43.2)
M. genitalium 0.0 (0.0–11.8)
Active syphilis, NG, or CT 19.7 (9.0–43.2)
Active syphilis, NG, CT, or TV 35.4 (21.0–59.9)
Active syphilis, NG, CT, TV, or MG 35.4 (21.0–59.9)
AB = antibodies; CI = confidence interval; CT = C. trachomatis; FSW = female sex worker; HBc = hepatitis B core; HBs = hepatitis B surface; HBV = hepatitis B virus; HCV =
hepatitis C virus; IgG/M = immunoglobulin G/M; IU = international units; MG = M. genitalium; NG = N. gonorrhoeae; PHQ = patient health questionnaire; RPR = rapid plasma
reagin; STI = sexually transmitted infection; TV = T. vaginalis; VDRL = venereal diseases research laboratory. * “No private sex life” was an item only displayed to participants
indicating having been paid for sex. † Participants were shown a comprehensive list of STI symptoms and asked if they currently had any of them.
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Gonorrhoea
In men, urethral infection with gonorrhoea is symptomatic
in approximately 90% of individuals [13]. In women, the
proportion of asymptomatic carriers appears significantly
higher [14]. Since we used pooled sampling (vaginal, pha-
ryngeal, rectal) we are unable to identify the fraction of
pharyngeal infection in this sample. However, given that
FSWs performing condomless oral sex on their clients is
common [15], it is likely that a substantial part of the 5%
gonorrhoea cases were pharyngeal carriers.
The risk of female to male transmission in the case of an
asymptomatic carrier of gonorrhoea is not well known and
the role of saliva in transmission of gonorrhoea has re-
cently been disputed [16]. However, given the high preva-
lence of condomless fellatio with FSWs in Switzerland and
the potential of oral transmission of gonorrhoea, sex with
Figure 1: Sexually transmitted infections among female sex workers at baseline (n = 490) and during follow-up (n = 42 over 46 follow-up vis-
its; 25.4 years of follow-up); percent with 95% confidence interval. CT = C. trachomatis; MG = M. genitalium; NG = N. gonorrhoeae; TV = T.
vaginalis.
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(A)OR = (adjusted) Odds Ratio; CAVI = condomless anal or vaginal intercourse; CI = confidence interval; CT = C. trachomatis; MG = M. genitalium; NG = N. gonorrhoeae; STI
= sexually transmitted infection; TV = T. vaginalis. Data presented are crude and adjusted odds ratios (bold if p <0.05) with 95% confidence intervals. Combined endpoints:
diagnosis of active syphilis, NG, or CT; and – in italics – diagnosis of active syphilis, NG, CT, TV, or MG among women.
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FSWs might contribute substantially to the spread of gon-
orrhoea among heterosexuals.
T. vaginalis
Among FSWs, T. vaginalis was the most frequently de-
tected single pathogen (10%). Despite a large amount of
epidemiological data on T. vaginalis in FSWs in Asia and
Africa [17], information is limited for Europe. Ten years
ago, a German survey on over 9000 FSWs found a 3%
prevalence for T. vaginalis [6], whereas another German
study in more marginalised FSWs found a higher preva-
lence (11%) [18].Here, we found a striking difference in
prevalence rates among FSWs (10%) vs other women
(0%). This clearly indicates sexual exposure as a primary
risk factor for this infection. In men, symptomatic infec-
tions with T. vaginalis and complications are rare. Little is
known about the rate of severe complications of T. vagi-
nalis infection in women but an association with cervical
neoplasia has been reported [19], possibly explained by an
increased susceptibility to HPV.
For financial and logistic reasons, most screening pro-
grammes in Switzerland for FSWs do not include T. vagi-
nalis. Nucleic acid amplification test kits are only available
for multiple pathogens and therefore T. vaginalis is rarely
tested in asymptomatic women. However, given the high
prevalence of T. vaginalis particularly in FSWs, screening
of asymptomatic FSWs might be a reasonable intervention,
although alternative diagnostic procedures might need to
be evaluated.
C. trachomatis
Since anal chlamydia infection in women is not associated
with anal intercourse [20], we included anal swabbing in
our pooling strategy regardless of sexual practices. C. tra-
chomatis was found in 6.3% of FSWs – a prevalence not
significantly higher than among other multi-partner
women (5.4%). Whether C. trachomatis screening should
be offered in women is highly debated, since such pro-
grammes do not appear to prevent a reasonable fraction
of cases with pelvic inflammatory diseases or infertility in
women [21], but result in an increased number of recur-
rent infections [22]. Unlike T. vaginalis, prevalence rates
for C. trachomatis and M. genitalium were very similar in
the two groups (table 2). The major epidemiological fac-
tors associated with risk of incident chlamydial infection
were young age and less than 2 years of sex work [23, 24].
There is some evidence for the acquisition of an immune
response against chlamydia if the infection is not treated
[23], a potential argument against screening. On the other
hand, early detection and treatment in FSWs might have a
beneficial role on the spread of chlamydia due to the large
number of exposed partners. As most detection assays for
N. gonorrhoeae are combined with C. trachomatis, our op-
tions to select the pathogens for screening are limited.
M. genitalium
The prevalence of MG colonisation was exactly the same
in FSWs as in other women. We are faced with a similar
situation as for C. trachomatis. The majority of M. geni-
talium infections remain asymptomatic. The role of sexual
exposure on the prevalence of M. genitalium remains un-
clear and we therefore suggest that M. genitalium screen-
ing should not be part of a screening programme in asymp-
tomatic FSWs.
HIV
Only one FSW, a transgender woman, was found to be HIV
positive in this study. Transgender FSWs have also been
found to have a higher HIV prevalence in a study from
Portugal [25].The low prevalence of HIV among cisgen-
der FSWs might reflect a selection bias against FSWs who
inject drugs. Low HIV prevalence was also found in oth-
er European studies of FSWs not injecting drugs [26–28].
This supports the finding from molecular epidemiological
studies that ongoing HIV transmission among cisgender
heterosexuals in Switzerland is extremely rare [29]. Never-
theless, given the high number of exposed partners and the
potential risk of sexual transmission of untreated HIV, any
strategy to offer STI testing to FSWs should include HIV
testing.
Hepatitis B and C, self-reported HPV vaccination
This study confirms that (hetero)sexual contact is not a rel-
evant mode of transmission of HCV [30]. Only one FSW
was found with active HCV infection, which is in the range
of prevalence in the general population [31].
Unlike HCV, HBV is often transmitted via sexual contacts.
In Switzerland, hepatitis B vaccination is recommended
and reimbursed for all adolescents, as well as for men
and women with “frequently changing partners” [32]. All
women in this study would thus be eligible for vaccination.
Recruited FSWs had a high prevalence (16%) of past HBV
infection, a relevant rate of active HBV infection (1.5%),
and half lacked protection against HBV. This finding sup-
ports efforts to promote HBV vaccination among FSWs.
At the time of enrolment into this study, HPV vaccination
was recommended and reimbursed for females younger
than 27 [33]. FSWs in Switzerland lack protection and can
therefore be regarded as relevant sources for HPV trans-
mission to their (unvaccinated) clients.
Strengths and limitations
To our knowledge, this is the first and largest study ever
performed on the prevalence of STIs in FSWs in Switzer-
land. The use of a multi-pathogen PCR method including
trichomonas, mycoplasma and ureaplasma was useful to
determine the relevance of some of these pathogens for
public health.
Unfortunately, we did not reach the power needed for more
precise estimates for incident STIs. There was a trend to-
wards more diagnoses during follow-up as compared with
baseline, possibly reflecting a self-selection bias, with
women with previous STIs more likely to return for fol-
low-up.
One methodological limitation was the pooling of vaginal,
pharyngeal and anal samples for PCR analysis. As a conse-
quence, we were unable to specify the location of pathogen
shedding. Data collected from a 2016 randomised con-
trolled trial and an in vitro study found that the mouthwash
Listerine® significantly reduced the amount of N. gonor-
rhoeae on the pharyngeal surface [34]. In our questionnaire
assessing specific risk behaviour we did not include the
routine use of mouthwash as a precautionary behaviour for
pharyngeal gonorrhoea.
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A major limitation of this study was that FSWs were al-
most entirely (97%) recruited in the German-speaking part
of Switzerland. Investigators from a large drop-in health
centre for FSWs in Geneva (ASPASIE) conducted a simi-
lar study from March 2017 to March 2019 [35]. The 95%-
confidence intervals of the prevalence rates of that study
did overlap with the results presented here, hence there
was no statistically significant difference in the prevalence
of HIV, syphilis, N. gonorrhoea, C. trachomatis, and un-
cleared hepatitis B infection between FSWs in the Ger-
man-speaking and the French-speaking part of Switzerland
(table S1 in appendix 1).
Conclusions
HIV and HCV do not appear to pose a major problem
among FSWs in Switzerland, while vaccination against
HBV should be promoted in this population. Non-viral
STIs, particularly syphilis and gonorrhoea, appear to have
a major impact in this population and screening of asymp-
tomatic FSWs might help to reduce the spread of these
pathogens. The importance of T. vaginalis infection seems
underestimated in FSWs and merits further studies. The
epidemiology of C. trachomatis and M. genitalium appears
to be less driven by sexual exposure, which renders screen-
ing of FSWs for these pathogens less important. Given the
high prevalence of non-viral STIs in this study and the sub-
stantial risk of onward transmission, low-cost or free rou-
tine screening of FSWs should be a public health priority.
Preliminary data of this study were presented at the 31st
annual IUSTI Europe conference in Helsinki, Finland
(IUSTI17-47, IUSTI17-53) in August/September 2017, and
at the Swiss HIV&STI Forum in March 2018.
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Appendix 1: Methods in detail
The appendix is available as a separate file at
https://smw.ch/article/doi/smw.2020.20393.
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